Search clinical trials for: Relapsing after allogeneic transplantation

Total 33806 results

M.D. Anderson Cancer Center

Withdrawn

PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation

Chronic Myelogenous Leukemia
Fondazione IRCCS Istituto Nazionale dei Tumori,...

Completed

TARC After alloSCT in Hodgkin's Lymphoma (TARC)

Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation

Italy
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of Edinburgh

Unknown

Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation

Lymphoproliferative Disorder

United Kingdom
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Terminated

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Northside Hospital, Inc.

Completed

Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Lymphoma

United States, Australia, Canada
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Terminated

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Cancer Research UK

Unknown

Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

Hematopoietic/Lymphoid Cancer

United Kingdom
University Hospital Birmingham

Unknown

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Graft Versus Host Disease | Nonneoplastic Condition

United Kingdom
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
European Working Group of MDS in Childhood

Unknown

Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

Germany, Austria, Switzerland, Czech Republic, Netherlands, Denmark, Belgium, Italy, Poland
Dana-Farber Cancer Institute
Brigham and Women's Hospital; Millennium Pharmaceuticals, Inc.

Completed

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

Hematologic Malignancies

United States
Washington University School of Medicine

Terminated

Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

Cytomegalovirus Infections

United States
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Lymphoma | Leukemia

United States
University Hospital Carl Gustav Carus

Completed

Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation

Chronic Myeloid Leukemia

Germany
University Hospital, Clermont-Ferrand
Pierre Fabre Laboratories

Unknown

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia (RICAC)

Chronic Lymphocytic Leukemia | Lymphocytic Lymphoma

France
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative Diseases

United States
National Cancer Institute (NCI)

Completed

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Asan Medical Center
Korea Research Institute of Bioscience & Biotechnology

Completed

Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

Korea, Republic of
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaborators

Unknown

Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant

Mesenchymal Stem Cells | Hematological Diseases | Stem Cell Transplantation, Hematopoietic | Poor Graft Function

China
Assistance Publique - Hôpitaux de Paris
Pierre and Marie Curie University; Paris 12 Val de Marne University

Completed

Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation (ILD-TK01)

Hematological Malignancy

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
University of California, San Francisco
National Cancer Institute (NCI)

Withdrawn

Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases

United States
Rabin Medical Center

Unknown

Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation

Graft Versus Host Disease

Israel
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Leukemia | Myelodysplastic Syndrome

United States
University Hospital Regensburg
ClinAssess GmbH

Unknown

A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT (IFN_BOSZT_01)

Steroid-refractory Bronchiolitis Obliterans

Germany
Northwestern University
National Cancer Institute (NCI)

Completed

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Sarcoma | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Rabin Medical Center

Unknown

PETCT for Diagnosing and Monitoring Acute GVHD (PETGVHD-001)

Acute Graft Versus Host Disease

Israel
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

Hematologic Malignancies | Graft Versus Host Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer

Lymphoma | Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation

Sarcoma | Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Testicular Germ Cell Tumor | Breast Cancer | Chronic Myeloproliferative Disorders | Ovarian Cancer | Gestational Trophoblastic Tumor | Neuroblastoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center

Completed

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Lymphoma | Leukemia | Graft Versus Host Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia

Leukemia

United States
University of Liege

Completed

Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC)

Hematologic Malignancies

Belgium
University of Arkansas

Terminated

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Multiple Myeloma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

France
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic-Myeloproliferative Diseases | Neuroblastoma | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Therapy-related Toxicity

United States
University Hospital, Clermont-Ferrand

Unknown

Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Benign Disease

France
Grupo Espanol de trasplantes hematopoyeticos y...

Unknown

Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH

Allogeneic Stem Cell Transplantation
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
Fred Hutchinson Cancer Center

Completed

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

United States

Search clinical trials for: Relapsing after allogeneic transplantation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations